NDAORAL-28TABLET
Approved
Mar 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OVCON-35 (ethinyl estradiol; norethindrone) by AbbVie. Approved for pregnancy. First approved in 1976.
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OVCON-35 is a combination oral contraceptive tablet containing ethinyl estradiol and norethindrone, approved in 1976 for pregnancy prevention. It is a small-molecule hormonal contraceptive that works by suppressing ovulation through estrogen and progestin receptor agonism. The product is administered as a 28-day oral tablet regimen.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely consolidating around defensive strategies and cost management rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
With zero linked job postings and LOE-approaching lifecycle status, OVCON-35 represents a sunset career opportunity at AbbVie. Roles on this product focus on defending market share, managing generic erosion, and optimizing cost structure rather than driving growth or innovation.
Brand Manager
Worked on OVCON-35 at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.